Stef Koppelman

Stef Koppelman

orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2021 in Trends in Food Science & Technology
Verified
Journal Article
Closed access
STSteve Taylor
Steve Taylor
JMJustin T. Marsh
Justin T. Marsh
SKStef Koppelman
Stef Koppelman
JKJamie L. Kabourek
Jamie L. Kabourek
PJPhilip E. Johnson
Philip E. Johnson
JBJoseph L. Baumert
Joseph L. Baumert

5 July 2016 in Scientific Reports
Verified
Journal Article
Open access
DADanijela Apostolovic
Danijela Apostolovic
DSDragana Stanic-Vucinic
Dragana Stanic-Vucinic
HJHarmen H. J. de Jongh
Harmen H. J. de Jongh
GJGovardus A. H. de Jong
Govardus A. H. de Jong
JMJelena Mihailovic
Jelena Mihailovic
SKStef Koppelman
Stef Koppelman
Conglutins represent the major peanut allergens and are renowned for their resistance to gastro-intestinal digestion. Our aim was to characterize the digestion-resistant peptides (DRPs) of conglutins by biochemical and biophysical methods followed by a molecular dynamics simulation in order to better understand the molecular basis of food protein allergenicity. We have mapped proteolysis sites at the N- and C-termini and at a limited internal segment, while other potential proteolysis sites remained unaffected. Molecular dynamics simulation showed that proteolysis only occurred in the vibrant regions of the proteins. DRPs appeared to be conformationally stable as intact conglutins. Also, the overall secondary structure and IgE-binding potency of DRPs was comparable to that of intact conglutins. The stability of conglutins toward gastro-intestinal digestion, combined with the conformational stability of the resulting DRPs provide conditions for optimal exposure to the intestinal immune system, providing an explanation for the extraordinary allergenicity of peanut conglutins.

1 May 2016 in Food and Chemical Toxicology
Verified
Journal Article
Closed access
SKStef Koppelman
Stef Koppelman
SJShyamali Jayasena
Shyamali Jayasena
DLDion Luykx
Dion Luykx
ESErik Schepens
Erik Schepens
DADanijela Apostolovic
Danijela Apostolovic
SMSoheila Maleki
Soheila Maleki

28 July 2018 in Pediatric Allergy and Immunology
Verified
Journal Article
Open access
PDF file
BRBenjamin C. Remington
Benjamin C. Remington
TKTanja Krone
Tanja Krone
SKStef Koppelman
Stef Koppelman
Background: The clinical relevance of increasing an allergic individual's peanut sensitivity threshold by immunotherapy, that is, eliciting dose (ED) to 300 or 1000 mg peanut protein, has not been previously characterized in a European population. In this study, we quantify the clinical benefits of an increased threshold of reaction following immunotherapy for the peanut‐allergic individual.Methods: Quantitative risk assessments incorporated numerous inputs to predict the risk of an allergic reaction after exposure to residual peanut protein in packaged foods. The three primary inputs for the risk assessment were the peanut‐allergic individual's clinical threshold value, the amount of food consumed per eating occasion of selected packaged foods, and the concentration of peanut protein in the consumed product. Individual risk reductions were calculated for both children and adolescents‐adults.Results: Using available consumption and packaged food contamination data, children reaching an ED of 300 mg (if initial ED ≤ 100 mg) or 1000 mg (if initial ED 300 mg) achieved >99.99% risk reduction. Adolescents‐adults also achieved >99.99% risk reduction in all cases but one. Adolescents‐adults who reached an ED of 300 mg (if initial ED ≤ 100 mg) achieved 99.3%‐99.9% risk reduction when consuming ice cream.Conclusions: It is concluded that an increase in threshold following immunotherapy which achieves an eliciting dose of 300 or 1000 mg peanut protein is clinically relevant for the European peanut‐allergic population. Benefits of an increased threshold include a significant reduction in risk due to traces of peanut protein.

1 January 2013 in BioMed Research International
Verified
Journal Article
Open access
PDF file
HJHarmen H. J. de Jongh
Harmen H. J. de Jongh
CLCarlos Lopez-Robles
Carlos Lopez-Robles
ETEefjan Timmerman
Eefjan Timmerman
JNJulie A. Nordlee
Julie A. Nordlee
PLPoi-Wah Lee
Poi-Wah Lee
SKStef Koppelman
Stef Koppelman
Food-processing conditions may alter the allergenicity of food proteins by different means. In this study, the effect of the glycosylation as a result of thermal treatment on the digestibility and IgE-binding of codfish parvalbumin is investigated. Native and glycosylated parvalbumins were digested with pepsin at various conditions relevant for the gastrointestinal tract. Intact proteins and peptides were analysed for apparent molecular weight and IgE-binding. Glycosylation did not substantially affect the digestion. Although the peptides resulting from digestion were relatively large (3 and 4 kDa), the IgE-binding was strongly diminished. However, the glycosylated parvalbumin had a strong propensity to form dimers and tetramers, and these multimers bound IgE intensely, suggesting stronger IgE-binding than monomeric parvalbumin. We conclude that glycosylation of codfish parvalbumin does not affect the digestibility of parvalbumin and that the peptides resulting from this digestion show low IgE-binding, regardless of glycosylation. Glycosylation of parvalbumin leads to the formation of higher order structures that are more potent IgE binders than native, monomeric parvalbumin. Therefore, food-processing conditions applied to fish allergen can potentially lead to increased allergenicity, even while the protein’s digestibility is not affected by such processing.

1 October 2020 in Food Chemistry
Verified
Journal Article
Closed access
HJHarmen H.J. de Jongh
Harmen H.J. de Jongh
GJGovardus A.H. de Jong
Govardus A.H. de Jong
DADanijela Apostolovic
Danijela Apostolovic
STSteve L. Taylor
Steve L. Taylor
JBJoseph L Baumert
Joseph L Baumert
SKStef Koppelman
Stef Koppelman